Literature DB >> 23499762

HGF and IGF-1 synergize with SDF-1α in promoting migration of myeloma cells by cooperative activation of p21-activated kinase.

Torstein Baade Rø1, Toril Holien, Unn-Merete Fagerli, Håkon Hov, Kristine Misund, Anders Waage, Anders Sundan, Randi Utne Holt, Magne Børset.   

Abstract

Stromal-derived factor (SDF)-1α, insulin-like growth factor (IGF)-1 and hepatocyte growth factor (HGF) are potent mediators of cell migration. We studied the effect of combinations of these cytokines on the migration of myeloma cells. When SDF-1α was combined with either HGF or IGF-1, we found a striking synergy in the cytokines' ability to guide cells across a transwell membrane. Between HGF and IGF-1 there was no cooperativity. However, the effects of HGF and IGF-1 were not redundant. HGF and SDF-1 caused concentration gradient-directed migration, as opposed to IGF-1, which apparently caused randomly directed cell movement. The SDF-1α-driven migration of JJN-3 cells, a myeloma cell line secreting large amounts of HGF, was reduced when JJN-3 cells were given an inhibitor of the HGF receptor, demonstrating a cooperative activity between autocrine HGF and exogenous SDF-1α. There was a clear positive correlation between the degree of cytokine-induced migration and phosphorylation of p21-activated kinase (PAK) both in primary myeloma cells and in cell lines including INA-6 and IH-1. Downregulation of PAK with small interfering RNA in INA-6 cells resulted in decreased cytokine-driven migration. This study shows synergy between SDF-1α and HGF/IGF-1 in inducing migration of myeloma cells, yet each cytokine has distinct properties in the way it regulates cell migration. These findings are likely to be of clinical relevance because multiple myeloma cells are located in an environment containing HGF and IGF-1 and are exposed to an SDF-1α gradient between the bone marrow and peripheral blood.
Copyright © 2013 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23499762     DOI: 10.1016/j.exphem.2013.03.002

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  14 in total

Review 1.  Dysregulated glycolysis as an oncogenic event.

Authors:  Takumi Mikawa; Matilde E LLeonart; Akifumi Takaori-Kondo; Nobuya Inagaki; Masayuki Yokode; Hiroshi Kondoh
Journal:  Cell Mol Life Sci       Date:  2015-01-22       Impact factor: 9.261

2.  Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.

Authors:  Mariateresa Fulciniti; Joaquin Martinez-Lopez; William Senapedis; Stefania Oliva; Rajya Lakshmi Bandi; Nicola Amodio; Yan Xu; Raphael Szalat; Annamaria Gulla; Mehmet K Samur; Aldo Roccaro; Maria Linares; Michele Cea; Erkan Baloglu; Christian Argueta; Yosef Landesman; Sharon Shacham; Siyuan Liu; Monica Schenone; Shiaw-Lin Wu; Barry Karger; Rao Prabhala; Kenneth C Anderson; Nikhil C Munshi
Journal:  Blood       Date:  2017-01-17       Impact factor: 22.113

3.  The serine protease matriptase inhibits migration and proliferation in multiple myeloma cells.

Authors:  Ida Steiro; Esten N Vandsemb; Samah Elsaadi; Kristine Misund; Anne-Marit Sponaas; Magne Børset; Pegah Abdollahi; Tobias S Slørdahl
Journal:  Oncotarget       Date:  2022-10-20

Review 4.  p21-Activated kinases as promising therapeutic targets in hematological malignancies.

Authors:  Andrew Wu; Xiaoyan Jiang
Journal:  Leukemia       Date:  2021-10-25       Impact factor: 11.528

5.  MicroRNA-7-5p mediates the signaling of hepatocyte growth factor to suppress oncogenes in the MCF-10A mammary epithelial cell.

Authors:  Dawoon Jeong; Juyeon Ham; Sungbin Park; Seungyeon Lee; Hyunkyung Lee; Han-Sung Kang; Sun Jung Kim
Journal:  Sci Rep       Date:  2017-11-13       Impact factor: 4.379

6.  The Chemokine Receptor CXCR4 and c-MET Cooperatively Promote Epithelial-Mesenchymal Transition in Gastric Cancer Cells.

Authors:  Yu Cheng; Yongxi Song; Jinglei Qu; Xiaofang Che; Na Song; Yibo Fan; Ti Wen; Ling Xu; Jing Gong; Xiaoxun Wang; Chenlu Zhang; Xiujuan Qu; Yunpeng Liu
Journal:  Transl Oncol       Date:  2018-02-27       Impact factor: 4.243

7.  Circulating healing (CH) cells expressing BST2 are functionally activated by the injury-regulated systemic factor HGFA.

Authors:  Claudia Lo Sicco; Daniele Reverberi; Federico Villa; Ulrich Pfeffer; Rodolfo Quarto; Ranieri Cancedda; Roberta Tasso
Journal:  Stem Cell Res Ther       Date:  2018-11-08       Impact factor: 6.832

8.  HGF, sIL-6R and TGF-β1 Play a Significant Role in the Progression of Multiple Myeloma.

Authors:  Artur Jurczyszyn; Jacek Czepiel; Grażyna Biesiada; Joanna Gdula-Argasińska; Dorota Cibor; Danuta Owczarek; William Perucki; Aleksander B Skotnicki
Journal:  J Cancer       Date:  2014-06-11       Impact factor: 4.207

9.  Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation.

Authors:  Derek James Hanson; Shingen Nakamura; Ryota Amachi; Masahiro Hiasa; Asuka Oda; Daisuke Tsuji; Kohji Itoh; Takeshi Harada; Kazuki Horikawa; Jumpei Teramachi; Hirokazu Miki; Toshio Matsumoto; Masahiro Abe
Journal:  Oncotarget       Date:  2015-10-20

Review 10.  The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential.

Authors:  Liesbeth Bieghs; Hans E Johnsen; Ken Maes; Eline Menu; Els Van Valckenborgh; Michael T Overgaard; Mette Nyegaard; Cheryl A Conover; Karin Vanderkerken; Elke De Bruyne
Journal:  Oncotarget       Date:  2016-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.